Press Releases
- DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value September 16, 2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... Read More
- AmericaFirst Funds Trust Announces Changes to Board of Trustees September 10, 2024
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and... Read More
- DSS, Inc. Names Jason Grady as Interim Chief Executive Officer August 26, 2024
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as... Read More
- Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." January 30, 2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative... Read More
About DSS
DSS focuses on operating business segments in blockchain security, consumer, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets.
The DSS business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs.